Superworth

Zevra Therapeutics price to free cash flow ZVRA

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Nov 2, 2026
18.4×
4-year median
21.0×
Against its 4-year history
29th
percentile: 0 is its lowest day, 100 its highest
4-year range
15.0× to 68.9×
Peer median
7.5×

Zevra Therapeutics' price to free cash flow is 18.4× as of Nov 2, 2026.

That is below its 4-year median of 21.0×, lower than on 71% of days in the last 4 years.

Over that time it ranged from 15.0× in May 2022 to 68.9× in Jul 2026.

The median for 10 large drugmakers of a similar size is 7.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.4×17.9×68.9×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202222.3×15.0×23.5×

Against its peers

Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Zevra Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.